Earnings Ahead

SRPT - Sarepta Therapeutics Inc.

106.4 -1.88 -1.74

Sarepta Therapeutics Inc.

Sarepta Therapeutics Inc.

About

Profile

Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases.


Headquarters

Cambridge, Massachusetts, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

SRPT

The biopharma stock soared 37% after the U.S. Food and Drug Administration granted approval for an expanded use of Sareptas Elevidys gene therapy, which would treat patients with Duchenne muscular dystrophy. The therapy was traditionally approved for all patients 4 years or older who are able to walk, with accelerated approval given for those who cannot walk.


 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Sarepta Therapeutics GAAP EPS of -$0.46 beats by $0.80, revenue of $331.8M beats by $45.03M
  • Sarepta Therapeutics Q3 2023 Earnings Preview
  • Biggest stock movers today: Caterpillar, Arista Networks, BP, Pinterest and more
  • Sarepta in selloff after late-stage setback for Duchenne candidate
  • 5 stocks to watch on Tuesday: Sarepta Therapeutics, Pfizer, AMD and more
  • Sarepta Phase 3 study for DMD drug fails to meet primary endpoint
  • Mizuho doesn't see Sarepta price decline connected to EMBARK study
  • Sarepta Therapeutics Non-GAAP EPS of -$0.85 beats by $0.15, revenue of $261.2M beats by $5.36M
  • Sarepta Therapeutics Q2 2023 Earnings Preview
  • Acumen, BridgeBio, Arcus among BTIG's top healthcare picks for 2H 2023
  • Catalyst Watch: CPI, major bank earnings, Amazon Prime Day and CAVA ratings
  • Sarepta raises $102M from selling priority review voucher
  • Sarepta down 9% as Duchenne treatment gets narrow population approval
  • Sarepta Duchenne treatment wins FDA nod, but with smaller population (update)
  • Regenxbio, UPenn file second patent suit against Sarepta over DMD therapy
  • Catalyst watch: C3.ai and Salesforce earnings, Knife River debut, Kenvue ratings & Faraday Future event
  • Hot Stocks: ANF, URBN and PANW rise on earnings; A, XPEV fall on weak outlooks; OCGN slides
  • Sarepta says FDA needs more time to review muscular dystrophy drug
  • Billions of dollars at stake as FDA shortcut allows half-proven drugs - report
  • Argenx, Blueprint Medicines, Sarepta likely M&A targets - analyst

Earnings History

Date EPS / Forecast Revenue / Forecast
October 27, 2021 - / -1.83 - / 171.36M
August 4, 2021 -1.02 / -1.3 164.09M / 167.07M
May 5, 2021 -2.1 / -1.83 146.93M / 145.81M Beat!
March 1, 2021 -2.4 / -1.8 145.14M / 150.38M
November 5, 2020 -2.5 / -1.71 143.92M / 137.76M Beat!
August 5, 2020 -1.93 / -1.72 137.36M / 116.29M Beat!
May 6, 2020 -0.23 / -1.92 113.67M / 116.49M
February 26, 2020 -3.16 / -1.81 100.11M / 98.8M Beat!
November 7, 2019 -1.7 / -1.35 99.04M / 98.48M Beat!
August 7, 2019 -3.74 / -1.07 94.67M / 91.05M Beat!
May 8, 2019 -1.07 / -1.61 87.01M / 86.6M Beat!
February 27, 2019 -2.05 / -1.02 84.42M / 84.92M
October 24, 2018 -1.15 / -0.78 78.49M / 78.75M
August 8, 2018 -1.67 / -0.84 73.53M / 71.4M Beat!
May 3, 2018 -0.55 / -0.32 64.6M / 65.09M
February 26, 2018 - / -0.32 - / 55.57M
October 25, 2017 -0.76 / -0.85 45.95M / 40.77M Beat!
July 19, 2017 -0.46 / -0.77 35.01M / 22.38M Beat!
April 27, 2017 -0.71 / -0.81 16.34M / - Beat!
February 28, 2017 -0.71 / -0.45 5.42M / 46.83M
October 27, 2016 -1.18 / -0.52 - / 3.08M
Date Price Open High Low Vol Change
Jul 24 146 146.13
147.6
145.04
827K -1.11%
Jul 23 147.64 145.55
149.29
145.41
1.2M 0.88%
Jul 22 146.35 145.39
147.33
144.34
1.2M 0.51%
Jul 19 145.61 144.35
147.24
143.74
1.4M 1.27%
Jul 18 143.78 147.57
147.85
143.62
694K -2.12%
 
Jul 17 146.9 147.52
149.21
144.7
1.1M -1.4%
Jul 16 148.98 152.11
153.3
148.37
1.5M -2.42%
Jul 15 152.67 152.32
154.13
150.74
971K 0.37%
Jul 12 152.11 152.8
153.26
150.33
1.2M 0%
Jul 11 152.11 150.06
152.81
149.02
1.4M 1.92%
Jul 10 149.25 151
152.26
148.56
1.1M -0.67%
Jul 9 150.25 151.23
152.35
148.21
1.9M -0.81%
Jul 8 151.48 152.98
154.9
150.47
1.4M -0.16%
Jul 5 151.73 152.57
152.58
150.98
962K -0.9%
Jul 3 153.11 154
155.95
151.25
615K -0.71%
Jul 2 154.2 156.46
156.7
153.65
1.3M -1.63%
Jul 1 156.75 158
162.95
155.18
1.7M -0.79%
Jun 28 158 157.96
159.77
156
1.9M 0.03%
Jun 27 157.96 156.72
158.74
152.74
1.2M 0.67%
Jun 26 156.91 155.75
157.84
151.26
2.3M -0.73%
Jun 25 158.06 164.52
164.52
157.38
2.3M -3.53%
Jun 24 163.85 162.25
168.3
162
4.5M 1.95%
Jun 21 160.72 161.97
173.25
157.25
15.0M 30.14%
Jun 20 123.5 117.53
123.73
115.74
2.2M 5.09%
Jun 18 117.52 117.01
120.29
116.77
1.5M 0.59%
Jun 17 116.83 122.53
122.55
116.5
1.4M -4.89%
Jun 14 122.84 124.09
125.89
120.34
1.0M -1.73%
Jun 13 125 122.22
125.84
122.22
2.2M 4.18%
Jun 12 119.98 122.93
123.53
118.7
702K -1.15%
Jun 11 121.38 121.48
122.56
119.62
682K -0.99%
Jun 10 122.59 123.13
124.41
121.68
1.6M -0.59%
Jun 7 123.32 117.53
124.6
116.52
1.5M 5.01%
Jun 6 117.44 119.2
119.44
116.93
1.3M -1.96%
Jun 5 119.79 119.75
122.53
116.5
1.8M 0.06%
Jun 4 119.72 123.79
124.22
118.87
1.1M -3.63%
Jun 3 124.23 128.53
128.53
122.64
1.8M -4.34%
May 31 129.86 125.48
130.81
125.4
17.0M 4.35%
May 30 124.45 122.95
125.72
120.23
4.4M 7.05%
May 29 116.25 113.37
117.08
112.39
1.9M 2.58%
May 28 113.33 119.02
120
109.91
3.0M -8.21%
May 24 123.46 128
129
123.31
1.0M -2.89%
May 23 127.13 128.12
129.84
125.5
848K -0.91%
May 22 128.3 128.93
130.94
127.66
723K -0.64%
May 21 129.12 130.11
131.02
127.68
748K -1.31%
May 20 130.83 132.15
132.15
128.75
780K -0.42%
May 17 131.38 132.88
133.12
129.5
849K -1.02%
May 16 132.74 132.04
133.06
129.56
1.0M 0.18%
May 15 132.5 134
134.71
132.1
763K -0.12%
May 14 132.66 133.55
134.34
130.89
1.2M 0.73%
May 13 131.7 132.25
133.55
129.78
634K -0.09%
May 10 131.82 132.87
132.87
129.44
736K -0.36%
May 9 132.3 133.22
133.39
129.49
1.3M -0.21%
May 8 132.58 137.14
137.14
129.45
1.6M -2.54%
May 7 136.04 135.1
146.68
132.3
2.0M 0.74%
May 6 135.04 133.6
135.16
132.62
823K 1.03%
May 3 133.66 132.55
134.46
131.16
1.2M 2.32%
May 2 130.63 140
142.79
130.05
2.2M -0.21%
May 1 130.9 127.06
131.61
127
1.2M 3.35%
Apr 30 126.66 128.65
129.7
126.53
1.1M -1.66%
Apr 29 128.8 129.02
131.8
127.47
1.0M 0%